AstraZeneca invests $2bn in Summit Therapeutics for cancer drug dealBy Martin Holloway29/09/2026 AstraZeneca’s $2bn Summit Therapeutics investment pairs preferred equity with a cancer drug trial tie-up, sending Summit shares sharply higher.
